KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biolife Solutions (BLFS) Non Operating Investment Income (2020 - 2024)

Biolife Solutions (BLFS) has disclosed Non Operating Investment Income for 4 consecutive years, with -$4.1 million as the latest value for Q2 2024.

  • On a quarterly basis, Non Operating Investment Income changed N/A to -$4.1 million in Q2 2024 year-over-year; TTM through Sep 2025 was -$4.1 million, a 0.0% change, with the full-year FY2024 number at -$4.1 million, changed N/A from a year prior.
  • Non Operating Investment Income was -$4.1 million for Q2 2024 at Biolife Solutions, down from -$411000.0 in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of $697000.0 in Q3 2022 to a low of -$4.1 million in Q2 2024.
  • A 4-year average of -$752600.0 and a median of -$184000.0 in 2022 define the central range for Non Operating Investment Income.
  • Biggest YoY gain for Non Operating Investment Income was 123.37% in 2023; the steepest drop was 123.37% in 2023.
  • Biolife Solutions' Non Operating Investment Income stood at $209000.0 in 2020, then surged by 233.49% to $697000.0 in 2022, then tumbled by 158.97% to -$411000.0 in 2023, then plummeted by 891.24% to -$4.1 million in 2024.
  • Per Business Quant, the three most recent readings for BLFS's Non Operating Investment Income are -$4.1 million (Q2 2024), -$411000.0 (Q1 2023), and $697000.0 (Q3 2022).